Mental health: use of medications by category in Chile 2028

Over the last two observations, the indicator 'Patients' is forecast to significantly increase in all segments. This reflects the overall trend throughout the entire forecast period from 2017 to 2028. It is estimated that the indicator is continuously rising in all segments. In this regard, the Anxiety and Related Sleep Disorders segment achieves the highest value of 1,537,353.05 users in 2028.

The Statista Market Insights cover a broad range of additional markets.

Number of users of medications treating mental health conditions in Chile from 2017 to 2028, by category

Characteristic	Anxiety and Related Sleep Disorders	Depressive Disorders	Psychotic Disorders
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Mental health disorders are common illnesses found among people all over the world. These disorders are caused by a variety of genetic and environmental factors that cause imbalances in a person's physical and emotional behavior. Most mental health disorders can be treated with behavioral and psychotherapies. In some cases, however, medication is prescribed along with these treatments. The Mental Health market represents the market for the drugs that are used to treat various mild to serious mental health disorders. The market is divided into three markets that have been based on the disorders that are being treated. This includes depressive disorders, anxiety and related sleeping disorders, and different types of psychotic disorders.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Pfizer, Bristol-Myers Squibb, Johnson & Johnson, AbbVie, and Sumitomo pharma

Citation formats